Uterine Polyps
One of three gynecological findings that are frequently confused with each other — alongside uterine fibroids and ovarian cysts — yet biologically entirely distinct: a localized, usually benign overgrowth of the uterine lining, often found incidentally, sometimes causing irregular bleeding, with a small but non-zero malignancy risk that depends on age and size.
Number of studies
3
Safety
Requires caution
Time to effects
Bleeding linked to a polyp usually resolves quickly after hysteroscopic polypectomy, often by the first cycle following the procedure; the uterine lining fully heals within a few weeks. With chosen observation, spontaneous resolution of some asymptomatic polyps is seen within about a year.
Who it's for
Table of contents
TL;DR
One of three gynecological findings that are frequently confused with each other — alongside uterine fibroids and ovarian cysts — yet biologically entirely distinct: a localized, usually benign overgrowth of the uterine lining, often found incidentally, sometimes causing irregular bleeding, with a small but non-zero malignancy risk that depends on age and size.
- →Hysteroscopic polypectomy combines diagnosis and treatment in a single procedure — the polyp is visualized, removed, and sent for histopathology all at once
- →Effectively and usually durably resolves abnormal uterine bleeding linked to the polyp
- →In women undergoing infertility treatment, removing a polyp projecting into the uterine cavity has been associated with improved pregnancy outcomes
| Type of lesion | A localized, usually benign overgrowth of the uterine lining (endometrium), distinct from fibroids and ovarian cysts |
|---|---|
| Level of evidence | Strong — well-characterized epidemiology, diagnostics, and malignancy-risk stratification |
| Prevalence | A few to several percent of women undergoing ultrasound/hysteroscopy for another reason, rising with age |
| Diagnostics | Transvaginal ultrasound, saline infusion sonohysterography, hysteroscopy (the diagnostic-and-therapeutic gold standard) |
| Malignancy risk — premenopausal | About 1.7% (Lee et al. meta-analysis, 2010) |
| Malignancy risk — postmenopausal | About 5.4%, roughly 3.9x higher relative risk than premenopausal |
| Natural course | A share of asymptomatic polyps regress spontaneously within a year of follow-up |
| Status | Requires individualized assessment — not every polyp needs immediate removal |
Understand
Overview
A uterine polyp (endometrial polyp) is a localized, usually benign overgrowth of the glands and stroma of the uterine lining (endometrium) that forms a projection bulging into the uterine cavity — attached by a stalk (a pedunculated polyp) or a broader base. Unlike uterine fibroids, which arise from smooth muscle, and ovarian cysts, which form within the ovary itself, a polyp develops exclusively from the lining of the uterine cavity — a third, biologically distinct category of gynecological findings, even though in everyday conversation these three phenomena get lumped together as 'something found on a pelvic ultrasound'.
Endometrial polyps are surprisingly common — depending on the population studied and the diagnostic method, they're found in a few to several percent of women undergoing ultrasound or hysteroscopy for another reason, and the detection rate rises with age, peaking around the perimenopausal period. A substantial share remain completely asymptomatic and are discovered incidentally during an ultrasound done for another reason — a routine gynecological check-up, an infertility workup, or surveillance of another pelvic finding.
In women who do have symptoms, the dominant one is abnormal uterine bleeding — most often irregular intermenstrual spotting, heavier or prolonged periods, and, in women past menopause, any bleeding from the genital tract at all, which is by definition already abnormal and warrants evaluation. Polyps are also sometimes an incidental finding during an infertility workup, since even a small polyp projecting into the uterine cavity can interfere with embryo implantation.
Diagnosis starts with transvaginal ultrasound, which in most women allows a reasonably sensitive suspicion of a polyp, especially in the second half of the cycle when the endometrium is thinner and the contrast with the polyp is clearer. Saline infusion sonohysterography (ultrasound with saline instilled into the uterine cavity) significantly improves diagnostic accuracy by outlining the lesion against the distended, saline-filled cavity. The definitive diagnostic-and-therapeutic gold standard is hysteroscopy — a procedure that allows the polyp to be directly visualized, sent for histopathology, and removed in the same session, combining diagnosis with treatment in a single step.
The most important clinical question when a polyp is found isn't 'is this dangerous', but what the real malignancy risk is for this specific lesion in this specific patient — and that depends above all on menopausal status. A large meta-analysis by Lee and colleagues, covering 17 studies and 10,572 women who underwent polypectomy, found neoplasia (malignant or premalignant) in 5.4% of polyps in postmenopausal women versus 1.7% in premenopausal women — nearly a fourfold difference in risk. Abnormal bleeding was also moderately associated with higher malignancy risk, though the effects of menopausal status and bleeding weren't found to be additive. Polyp size itself, in this meta-analysis's pooled data, wasn't clearly linked to malignancy risk, though some individual studies point to higher risk above 1.5 cm, especially in postmenopausal women.
Not every polyp needs immediate removal. Research on the natural course of asymptomatic polyps shows that a substantial share regress spontaneously within a year of follow-up, which is a strong argument for watchful waiting in selected, low-risk patients rather than automatically referring every woman with an incidentally found polyp for a procedure. The decision to remove one depends on a combination of factors: the presence and severity of symptoms (especially abnormal bleeding), menopausal status, lesion size, fertility plans, and additional risk factors such as tamoxifen therapy or prolonged, progestin-unopposed estrogen exposure.
It's worth stressing the distinction from two other frequently confused gynecological findings covered in our articles on uterine fibroids and ovarian cysts: fibroids arise from the uterine smooth muscle rather than the lining, with a completely different hormonal and symptom profile (mainly pressure symptoms and heavy bleeding tied to tumor size, not intermenstrual spotting); ovarian cysts form within the ovary itself, independent of the uterine cavity, and carry a different risk spectrum (including acute events like ovarian torsion). Polyps, fibroids, and ovarian cysts are three separate entities that can coexist in the same woman but require separate evaluation and separate treatment approaches.
Mechanism of action
An endometrial polyp forms through a localized overgrowth of endometrial glands and stroma, confined to a small area, around a central vascular core (a single, usually dilated spiral arteriole), which then rises and projects into the uterine cavity, forming the characteristic pedunculated or broad-based structure. Unlike normal endometrium, which grows and sheds cyclically as a whole in response to hormonal changes, polyp tissue shows relatively elevated estrogen receptor expression and a disrupted balance between estrogen and progesterone receptors, which makes it grow in a way that's partly independent of cyclic progesterone action — behaving locally similarly to tissue under chronic, unopposed estrogen stimulation, even while the rest of the endometrium cycles normally.
Molecular studies of a subset of polyps have found clonal chromosomal rearrangements in the stromal cells, indicating that at least some polyps arise as a genuine, localized monoclonal proliferative process rather than a simple, diffuse hyperplastic response of the whole endometrium to excess estrogen — despite this, the vast majority of polyps remain histologically entirely benign throughout their existence.
The polyp's central vascular core is structurally prone to venous congestion, superficial ulceration, and localized necrosis, which explains why bleeding associated with a polyp tends to be irregular and independent of the menstrual cycle — unlike bleeding from normal endometrium, which sheds on a predictable cyclic rhythm, bleeding from the polyp's damaged surface can occur at any point in the cycle, clinically presenting as unpredictable intermenstrual spotting.
Rare cases of malignant transformation occur through progressive atypical growth within the polyp's own tissue, rather than the lesion being malignant from the outset. The risk of such progression rises with age and postmenopausal status, most likely because prolonged, unopposed estrogen exposure — more common after menopause in women on estrogen-only hormone therapy or taking tamoxifen, a drug with partial estrogenic activity on the endometrium — promotes progressive atypical change in tissue already prone to unopposed estrogenic growth. This mechanism explains why menopausal status is the strongest, best-documented risk stratifier for malignancy identified in the available literature.
Localized overgrowth around a vascular core
Endometrial glands and stroma proliferate, confined to a small area around a central, dilated spiral arteriole.
Disrupted hormone receptor balance
Polyp tissue shows relatively elevated estrogen receptor expression and a disrupted response to progesterone, growing partly independently of the cycle.
Projection into the uterine cavity
The growing tissue rises and bulges into the uterine cavity, forming a pedunculated or broad-based structure.
Superficial damage and bleeding
The vascular core, prone to venous congestion, undergoes superficial ulceration, causing irregular bleeding independent of the cycle.
Rare atypical progression
In a small percentage of cases, more often after menopause, progressive atypical growth develops within the polyp tissue, which can lead to a malignant lesion.
Evidence: strong — based on 3 studies in this database.
Benefits
Common myths
MythA uterine polyp is basically the same thing as a uterine fibroid, just a different name.
FactThese are two biologically distinct findings — a polyp arises from the uterine lining (endometrium), while a fibroid arises from the uterine smooth muscle, which translates into a different symptom profile, different diagnostics, and different treatment.
MythEvery uterine polyp is a potential cancer that must be removed immediately.
FactThe vast majority of polyps are completely benign, and malignancy risk depends strongly on menopausal status — about 1.7% premenopausally and 5.4% postmenopausally. Some asymptomatic polyps, especially small ones in younger women, can be safely observed.
MythIf a polyp causes no symptoms at all, it doesn't need to be evaluated by definition.
FactAn asymptomatic polyp in a postmenopausal woman still warrants a risk assessment, since postmenopausal status itself significantly raises malignancy risk regardless of whether bleeding is present.
MythUterine polyps always cause heavy, easily noticed bleeding.
FactA substantial share of polyps are entirely asymptomatic and are found incidentally during an ultrasound done for another reason — the absence of symptoms doesn't rule out a polyp's presence.
MythTransvaginal ultrasound always clearly distinguishes a polyp from other uterine findings.
FactUltrasound is good at suggesting a polyp, but a definitive diagnosis and exclusion of malignancy requires hysteroscopy with histopathological examination of the removed tissue.
MythOnce a polyp is removed, there's no risk of another one forming.
FactPolyps can recur, especially when risk factors persist, such as ongoing tamoxifen therapy or unopposed estrogen exposure — hence periodic follow-up is reasonable in women with such risk factors.
MythSize is the most important factor determining a polyp's malignancy risk.
FactIn a large meta-analysis, menopausal status proved a stronger and more consistent risk factor than size alone, though some individual studies link larger polyps (above 1.5 cm) to higher risk, especially after menopause.
Forms & variants
Uterine Polyps comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Asymptomatic polyp (an incidental finding)
Detected during an ultrasound performed for another reason, without accompanying bleeding symptoms.
Best for: Often a candidate for watchful waiting, especially premenopausally and at a small size
Symptomatic polyp with abnormal bleeding
Causes intermenstrual spotting or heavy or prolonged menstrual bleeding.
Best for: Usually an indication for hysteroscopic polypectomy regardless of age
Polyp in a postmenopausal woman
Carries a significantly higher malignancy risk than in premenopausal women, regardless of whether symptoms are present.
Best for: Warrants a lower threshold for removal and histopathological verification
Polyp associated with tamoxifen therapy
More frequent and tends to be larger in women treated with tamoxifen for breast cancer, due to the drug's partial estrogenic action on the endometrium.
Best for: Requires regular gynecological surveillance during oncologic therapy
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
A polyp arises from the uterine lining (endometrium) and projects into its cavity, while a fibroid arises from the uterine smooth muscle and can grow within different layers of the uterine wall. They also differ in typical symptoms (polyps more often cause intermenstrual spotting, fibroids cause heavy bleeding and pressure symptoms tied to size) and treatment approach.
Yes, in some women, especially with small, asymptomatic premenopausal polyps, the lesion can regress spontaneously within about a year of follow-up. This isn't the rule, though, so the decision between observation and removal is best made together with a gynecologist, taking into account size, symptoms, and menopausal status.
The vast majority of polyps are completely benign. Malignancy risk is about 1.7% premenopausally, rising to about 5.4% postmenopausally, which means menopausal status is a key factor in deciding how urgently a lesion should be evaluated and possibly removed.
Hysteroscopic polypectomy is usually performed as outpatient or short-stay day surgery, with a return to daily activity most often within a few days. Discomfort after the procedure is usually moderate and well controlled with standard pain medication.
A polyp projecting into the uterine cavity can interfere with embryo implantation even when small, which is why its removal is often recommended for women undergoing an infertility workup regardless of other symptoms. Not every polyp affects fertility, but women trying to conceive should discuss this with their fertility specialist.
It doesn't mean certainty, but tamoxifen significantly raises the risk of endometrial polyp formation and growth due to its partial estrogenic activity on the uterine lining. Women treated with this drug for breast cancer usually have regular gynecological surveillance planned that accounts for this possibility.
Usually yes, especially in women with recurrence risk factors (tamoxifen therapy, unopposed estrogen exposure) — periodic ultrasound follow-up allows early detection of any recurrence. In women without additional risk factors and without recurring symptoms, the frequency of further follow-up is set individually with the physician.
What actually helps
Watchful waiting
Moderate evidenceA reasonable option for small, asymptomatic polyps in premenopausal women without additional risk factors — some such lesions regress spontaneously within a year.
Hysteroscopic polypectomy
Strong evidenceThe gold-standard treatment — simultaneous visualization, removal, and histopathological assessment of the polyp, recommended for abnormal bleeding, infertility, or elevated malignancy risk.
Follow-up transvaginal ultrasound or sonohysterography
Strong evidencePeriodic imaging assessment in patients choosing observation, allowing monitoring of lesion size and any progression.
Histopathological examination of removed tissue
Strong evidenceAn essential part of every polypectomy, allowing definitive exclusion of a premalignant or malignant lesion regardless of the lesion's imaging appearance.
Hormonal treatment to ease bleeding
Moderate evidenceProgestins or a levonorgestrel-releasing IUD can reduce the severity of abnormal bleeding, though they don't remove the polyp itself.
Reviewing tamoxifen or estrogen-only HRT therapy where clinically feasible
Moderate evidenceLimiting a modifiable risk factor in patients with recurrent polyps, coordinated with the physician managing the underlying treatment.
Urgent evaluation of postmenopausal bleeding
Strong evidenceAny genital bleeding after menopause warrants prompt gynecological evaluation given the elevated malignancy risk in this group.
Safety
Side effects & contraindications
Possible side effects
An untreated, symptomatic polyp with abnormal bleeding can lead to iron-deficiency anemia from chronic blood loss
Rarely: uterine perforation during hysteroscopy, usually without lasting consequences with an experienced operator
Rarely: intrauterine adhesions (Asherman's syndrome) after the procedure, which can affect fertility
Short-term spotting and light bleeding after polypectomy, usually resolving within a few days
A small risk of intrauterine infection after a hysteroscopic procedure
Risk of recurrence — polyps can regrow, especially when risk factors remain uncorrected (e.g. ongoing tamoxifen therapy)
Standard anesthesia-related risks if the procedure is performed under general anesthesia or deep sedation
In rare cases, an unrecognized malignant lesion if an atypical polyp is mistakenly classified as benign without histopathological examination
Contraindications
Active pelvic infection — requires treatment before an elective hysteroscopic procedure
Pregnancy — diagnostic-and-therapeutic hysteroscopy isn't performed during pregnancy
Uncorrected coagulopathy — requires evaluation and preparation before the procedure due to bleeding risk
Interactions
Tamoxifen — a drug with partial estrogenic activity on the endometrium, significantly raising the risk of polyp formation and growth in women treated for breast cancer
Estrogen-only hormone therapy — unopposed estrogen exposure increases the risk of polyp development and progression
Combined hormonal contraception and levonorgestrel-releasing IUDs — may reduce the risk of new polyps forming through their opposing progestin effect
Anticoagulant medications — increase bleeding risk during diagnostic workup and the procedure, requiring consideration when planning a polypectomy
Obesity — excess fat tissue increases peripheral conversion of androgens to estrogens, indirectly increasing estrogenic stimulation of the endometrium
Nonsteroidal anti-inflammatory drugs — used as needed to ease discomfort from bleeding, without affecting the polyp itself
Is it worth taking?
Who it's for
- Women with abnormal uterine bleeding — intermenstrual spotting or heavy/prolonged periods
- Postmenopausal women with any genital bleeding requiring urgent evaluation
- Women undergoing an infertility workup, where a polyp projecting into the uterine cavity may affect embryo implantation
- Women on tamoxifen or estrogen-only hormone therapy who need periodic gynecological surveillance
Not for
- Active pelvic infection — requires treatment before an elective hysteroscopic procedure
- Pregnancy — diagnostic-and-therapeutic hysteroscopy isn't performed during pregnancy
- Uncorrected coagulopathy — requires evaluation and preparation before the procedure due to bleeding risk
Evidence
Worth knowing
Endometrial polyps are found in a few to several percent of women undergoing ultrasound or hysteroscopy for another reason.
Malignancy risk is about 1.7% premenopausally and 5.4% postmenopausally — nearly a fourfold difference.
Hysteroscopy is the diagnostic-and-therapeutic gold standard, combining diagnosis, removal, and histopathology in a single procedure.
Some asymptomatic polyps, especially under 10 mm, regress spontaneously without treatment within about a year.
Tamoxifen, a breast cancer medication, significantly raises the risk of endometrial polyp formation and growth.
Any genital bleeding after menopause, regardless of how heavy, warrants gynecological evaluation.
Polyps, uterine fibroids, and ovarian cysts are three separate, independent entities that can coexist but require separate evaluation.
Studies
Neoplasia (malignant or premalignant change) was found in 5.4% of endometrial polyps in postmenopausal women versus 1.7% in premenopausal women — a relative risk roughly 3.9 times higher.
Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM, Obstetrics & Gynecology, 2010
The oncogenic potential of endometrial polyps: a systematic review and meta-analysis
Strong evidenceLee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM · Obstetrics & Gynecology · 2010
A meta-analysis of 17 studies covering 10,572 women who underwent polypectomy. Neoplasia (malignant or premalignant change) was found in 5.4% of polyps in postmenopausal women versus 1.7% premenopausally (relative risk about 3.9). Abnormal bleeding was associated with neoplasia at 4.2% versus 2.2% without bleeding, but the effects of menopausal status and bleeding weren't additive. Polyp size, in the pooled data, showed no clear link to malignancy risk.
View studyPrevalence, 1-year regression rate, and clinical significance of asymptomatic endometrial polyps: cross-sectional study
Moderate evidenceLieng M, Istre O, Sandvik L, Qvigstad E · Journal of Minimally Invasive Gynecology · 2009
A cross-sectional study of 257 randomly selected women aged 40-45 found endometrial polyps in 12.1% of them. After one year of follow-up, 27% of the identified, asymptomatic polyps had regressed spontaneously, supporting the case for watchful waiting in selected, low-risk patients rather than an immediate procedure.
View studyAAGL Practice Report: Practice Guidelines for the Diagnosis and Management of Endometrial Polyps
Strong evidenceAAGL Advancing Minimally Invasive Gynecology Worldwide · Journal of Minimally Invasive Gynecology · 2012
A practice guideline naming hysteroscopic polypectomy as the primary treatment method, discouraging 'blind' polyp removal when equipment for guided removal is available, and allowing conservative management in selected patients — with spontaneous regression reaching up to 25% of cases, especially for lesions under 10 mm.
View studySources & bibliography
- Lee et al. 2010 — Obstetrics & Gynecology
- Lieng et al. 2009 — Journal of Minimally Invasive Gynecology
- AAGL Practice Report 2012 — Journal of Minimally Invasive Gynecology
The PubMed identifiers in this knowledge base were checked against NCBI records (October 2026). If you spot an error in a source, please let us know via the contact form.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
227 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
297 publications on this site
Related entries
4.7Endometriosis
A chronic disease affecting about 10% of women of reproductive age, still diagnosed with a multi-year delay on average — despite pain severe enough to significantly disrupt daily functioning.
4.6Menopause
The permanent cessation of menstruation caused by the ovaries ceasing function — a turning point involving significant metabolic, cardiovascular, and bone changes that calls for deliberate prevention.
4.6Polycystic Ovary Syndrome (PCOS)
The most common hormonal disorder among women of reproductive age — it combines irregular cycles, excess androgens, and insulin resistance, but responds substantially to lifestyle changes.
Related articles
PoradnikiUterine Fibroids: Symptoms and Treatment — from Watchful Waiting to Surgery
Uterine fibroids are the most common benign tumor of the female reproductive organs — estimates range from a few percent to over 70%, depending on the diagnostic method and age, and for many women they remain symptom-free for life. For others they cause heavy, multi-day bleeding, pain, and pelvic pressure that genuinely reduce quality of life. We explain how the different fibroid types differ, when watchful waiting is enough, and when it's worth considering drug therapy, myomectomy, hysterectomy, or uterine artery embolization (UFE).
September 16, 2026
PoradnikiOvarian Cysts: When to Worry, and When to Just Keep Watching?
A cyst on the ovary found on ultrasound triggers worry almost automatically, even though the vast majority of such findings are harmless, functional cysts that disappear on their own within a few cycles. The problem is that the same word also covers rarer pathological changes that need monitoring or treatment, and — very rarely — acute situations like ovarian torsion that require immediate help. We explain how the different cyst types differ, which symptoms are normal, and which should prompt an urgent visit.
September 16, 2026
PoradnikiFibrocystic Breast Changes: Causes and Management
Tenderness, lumpiness, and a "grainy" feeling in the breasts just before a period affects up to 90% of women at some point in their lives — a phenomenon common enough that medicine long ago stopped calling it a disease. Fibrocystic breast changes (today more often called simply fibrocystic changes rather than "fibrocystic breast disease") don't themselves raise breast-cancer risk, but they can be a source of real discomfort and anxiety, especially when a new, palpable lump appears. We explain the hormonal mechanism behind these changes, what actually helps ease symptoms versus what's a myth, and when a breast lump needs urgent evaluation.
September 16, 2026
PoradnikiHormone Replacement Therapy in Menopause: Who Should Consider It, When, and What's the Real Risk?
The 2002 WHI study triggered a global panic around hormone replacement therapy, and prescriptions dropped by half almost overnight. Two decades of further analysis have painted a much more nuanced picture — one that depends above all on age and timing of initiation. We explain what the data actually show, who has a favorable risk-benefit balance today, and who should exercise particular caution.
August 22, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.
